Sclerosing cholangitis
MONDO:0018646A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.
Also known as: Primary sclerosing cholangitis, primary sclerosing cholangitis (PSC), sclerosing cholangitis, sclerosing cholangitis (disease)
55 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug trial aims to slow liver disease in rare bile duct condition
Disease control Recruiting nowThis Phase 3 study tests whether the drug elafibranor can slow liver damage in adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts. About 350 participants will receive either elafibranor or a placebo daily for several years. The main goal is…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a form of vitamin B12 help control a rare liver disease?
Disease control Recruiting nowThis Phase 2 trial tests whether the drug BRS201 (a form of vitamin B12) can improve liver health in people with primary sclerosing cholangitis (PSC), a rare liver disease. Over 8 weeks, 28 participants will take either the drug or a placebo for 4 weeks each, in random order. The…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New biodegradable stents offer hope for PSC patients
Disease control Recruiting nowThis study tests whether biodegradable stents can safely open narrowed bile ducts in 20 people with primary sclerosing cholangitis (PSC). The stents are placed during an endoscopic procedure and dissolve over time, aiming to improve symptoms like itching and fatigue and prevent t…
Phase: NA • Sponsor: King's College Hospital NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a fecal transplant help treat a rare liver disease?
Disease control Recruiting nowThis early-stage trial is testing whether a transplant of healthy gut bacteria can be safely given to people with primary sclerosing cholangitis (PSC), a rare liver disease. Twenty-eight adults will first take antibiotics to clear their gut, then receive capsules containing freez…
Phase: EARLY_PHASE1 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Poop pills could tame rare liver disease
Disease control Recruiting nowThis study tests whether transplanting healthy stool bacteria (FMT) can improve liver health in people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease. 58 adults will receive either FMT or a placebo via colonoscopy and enemas. The main goal is to see if F…
Phase: PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New PSC drug enters early safety testing in humans
Disease control Recruiting nowThis early-stage study tests whether the experimental drug TAK-781 is safe and tolerable in healthy volunteers and in people with primary sclerosing cholangitis (PSC), a chronic liver disease. The study also looks at how the body processes the drug. About 134 participants will be…
Phase: PHASE1 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug aims to stop immune system from attacking transplanted livers
Disease control Recruiting nowThis early study tests whether siplizumab, given at the time of liver transplant, can safely prevent the immune system from attacking the new liver. Up to 8 adults with autoimmune hepatitis or primary sclerosing cholangitis will receive two doses. The main goal is to check for se…
Phase: PHASE1 • Sponsor: Elizabeth C. Verna • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug LB-P8 aims to tame rare liver disease PSC
Disease control Recruiting nowThis study tests a new drug, LB-P8, in 87 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The goal is to see if LB-P8 is safe and can lower levels of alkaline phosphatase (ALP), a marker of liver damage. Participants will receive either LB-P8 or a placebo,…
Phase: PHASE2 • Sponsor: LISCure Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a common drug stop a rare liver disease from returning after transplant?
Prevention Recruiting nowThis study tests whether taking fenofibrate once daily for three years can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. The trial enrolls adults who had a liver transplant for PSC within the past 1 to 7 years and are at higher risk of re…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jul 19, 2026 00:00 UTC
-
Scientists launch deep dive into rare liver disease PSC
Knowledge-focused Recruiting nowThis study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. About 143 adults with PSC will provide blood, saliva, urine, stool, and tissue samples, plus undergo imaging and procedures like colonoscopy and liver biopsy. No treatmen…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Artificial intelligence may help decide who gets a liver first
Knowledge-focused Recruiting nowThis study tests whether artificial intelligence can more accurately predict which patients on the liver transplant waiting list are at highest risk of dying or becoming too sick for surgery. Researchers will follow 630 adults with severe liver disease or liver cancer across five…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
AI may outsmart current system for liver transplant priority
Knowledge-focused Recruiting nowThis European study is collecting health data from 4,500 adults listed for liver transplantation across 50 centers. The goal is to design and test new AI-based models that predict which patients are most likely to die or become too sick for transplant while waiting. If accurate, …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Bile duct battle: which backup technique works best?
Knowledge-focused Recruiting nowThis study compares two advanced techniques used when doctors have trouble reaching the bile duct during a procedure called ERCP. About 188 adults with difficult bile duct access will be randomly assigned to either an endoscopic ultrasound-guided rendezvous technique or an early …
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New study tracks rare liver disease in kids to uncover clues
Knowledge-focused Recruiting nowThis study follows 1,000 children with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. Researchers will collect medical data, DNA, and symptom reports over time to understand how the disease progresses and affects daily life. The goal is to ide…
Sponsor: Arbor Research Collaborative for Health • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Massive PSC study aims to create blueprint for faster drug trials
Knowledge-focused Recruiting nowThis study is gathering health information from 2,000 adults with primary sclerosing cholangitis (PSC) to build a real-world data comparator group. The goal is to help design and run future drug trials more efficiently by providing a control group from real patient experiences. P…
Sponsor: PSC Partners Seeking a Cure • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Gene hunt for mysterious adult liver disease
Knowledge-focused Recruiting nowThis study is using advanced whole-genome sequencing to find hidden genetic causes of cholestatic liver disease in adults whose condition remains unexplained after standard tests. Researchers will compare the DNA of 60 affected adults to a large group of healthy controls. The goa…
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists build mini livers to unlock genetic secrets of rare bile duct disease
Knowledge-focused Recruiting nowThis study aims to understand why some people develop a rare, serious liver disease called primary sclerosing cholangitis (PSC). Researchers will create 3D cell models from patient samples to study how specific genetic changes affect bile duct cells. The goal is to find new ways …
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Gut bacteria may hold key to liver disease mysteries
Knowledge-focused Recruiting nowThis study looks at the gut bacteria of 3000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria linked to each disease to better understand how the gut and liver interact. This is an observational study, not a …
Sponsor: Chungnam National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:04 UTC
-
Could a common cholesterol drug unlock secrets of a rare liver disease?
Knowledge-focused Recruiting nowThis early-phase study at Stanford University is testing whether the statin drug rosuvastatin changes bile acid levels and gut bacteria in people with primary sclerosing cholangitis (PSC), a liver disease with no cure. Researchers will enroll 15 adults with PSC and inflammatory b…
Phase: EARLY_PHASE1 • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Scientists grow tiny liver organoids from bile to unlock PSC secrets
Knowledge-focused Recruiting nowThis study collects bile and bile duct cells from people with Primary Sclerosing Cholangitis (PSC) and healthy volunteers to grow mini-livers called organoids. The goal is to understand how PSC progresses and leads to liver cancer. No treatment is given; it is purely for research…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Mayo clinic launches massive biobank to unlock secrets of rare liver diseases
Knowledge-focused Recruiting nowThis study is creating a large collection of blood, urine, stool, bile, and bile duct cells from up to 9,150 people with cholestatic liver diseases like primary biliary cholangitis and primary sclerosing cholangitis, as well as from healthy volunteers. The samples and medical dat…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New registry tracks best way to fix bile duct blockages in liver transplant patients
Knowledge-focused Recruiting nowThis study follows 40 liver transplant patients who develop non-anastomotic biliary strictures—narrowing of the bile ducts not at the connection point. Doctors use an endoscope to place plastic stents and then track how well the strictures resolve. The goal is to gather real-worl…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Albumin recovery time may forecast surgical outcomes
Knowledge-focused Recruiting nowThis study tracks 1,000 patients undergoing major liver, pancreas, or bile duct surgery to see if the time it takes for their albumin levels to return to normal can predict complications and length of hospital stay. Albumin is a protein that drops after surgery due to inflammatio…
Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Blood test could spot Immunotherapy-Linked liver damage
Knowledge-focused Recruiting nowThis study aims to identify specific blood markers that can distinguish hepatitis caused by immune checkpoint inhibitors from other types of autoimmune hepatitis. Researchers will collect blood samples and liver tissue from 60 adults receiving immunotherapy. The goal is to improv…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC